- Home
- RPRX vs AFRM Comparison
RPRX vs AFRM Comparison
Compare RPRX & AFRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | AFRM |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4B | 24.9B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RPRX | AFRM |
|---|---|---|
| Price | $70.15 | $67.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 36 |
| Target Price | $72.00 | ★ $96.22 |
| AVG Volume (30 Days) | 3.2M | ★ 3.9M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | N/A | ★ 3586.67 |
| EPS | ★ 1.03 | 0.47 |
| Revenue | $2,378,193,000.00 | ★ $4,261,082,000.00 |
| Revenue This Year | $49.27 | $31.17 |
| Revenue Next Year | $9.11 | $24.24 |
| P/E Ratio | ★ $67.27 | $140.55 |
| Revenue Growth | 5.06 | ★ 32.15 |
| 52 Week Low | $37.31 | $42.10 |
| 52 Week High | $69.77 | $90.44 |
Technical Indicators
Market Signals| Indicator | RPRX | AFRM |
|---|---|---|
| Relative Strength Index (RSI) | 77.70 | 43.44 |
| Support Level | $55.48 | $60.68 |
| Resistance Level | N/A | $70.02 |
| Average True Range (ATR) | 1.57 | 3.83 |
| MACD | 0.35 | -0.68 |
| Stochastic Oscillator | 95.66 | 27.91 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About AFRM Affirm Holdings Inc.
Founded in 2012, Affirm is a market leader in the buy now, pay later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant-subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also constitute the majority of its revenue. Affirm primarily operates in the United States, which accounted for more than 95% of its revenue in 2025, but it has also expanded to Canada and the United Kingdom.